Literature DB >> 18477126

Low-dose palliative splenic irradiation in haematolymphoid malignancy.

R K Shrimali1, P D Correa, N O'Rourke.   

Abstract

Patients are treated with palliative splenic irradiation (SI) to relieve pain, volume effects and the clinical consequences of hypersplenism. The case records of 19 patients treated with palliative SI at our centre, from April 2003 to November 2004, were reviewed. Twenty-two courses of SI were identified. The radiation doses delivered ranged from 150 to 800 cGy (median 450 cGy). The fraction sizes ranged from 25 to 100 cGy. Parallel-opposed anteroposterior-posteroanterior portals were the most common field arrangement. The target volume was reduced in 18 out of 22 courses. The percentage of field reduction ranged from 0 to 59.57% (mean 24.82%). Twelve of 14 courses were successful in achieving symptom palliation. Of the six patients who received SI for a combination of splenic symptoms and abnormal blood tests, five had symptomatic palliation but only one patient responded haematologically. Of two patients who were started on palliative SI for abnormal haematology alone, only one responded. In summary, 17 of 20 (85%) courses of SI initiated for symptom control resulted in effective palliation. Only two of eight (25%) courses of SI started for abnormal blood counts produced a desired response. To conclude, SI offers an effective and well-tolerated palliative treatment option.

Entities:  

Mesh:

Year:  2008        PMID: 18477126     DOI: 10.1111/j.1440-1673.2008.01958.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  4 in total

1.  Radiotherapy of splenomegaly : a palliative treatment option for a benign phenomenon in malignant diseases.

Authors:  Jan Kriz; Oliver Micke; Frank Bruns; Uwe Haverkamp; Ralph Mücke; Ulrich Schäfer; Heinrich Seegenschmiedt; Rolf-Peter Müller; Hans Theodor Eich
Journal:  Strahlenther Onkol       Date:  2011-03-07       Impact factor: 3.621

Review 2.  Methodologies in creating skin substitutes.

Authors:  Mathew N Nicholas; Marc G Jeschke; Saeid Amini-Nik
Journal:  Cell Mol Life Sci       Date:  2016-05-06       Impact factor: 9.261

3.  Radiation exposure of the spleen during (177)Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume.

Authors:  Johanna Svensson; Linn Hagmarker; Tobias Magnander; Bo Wängberg; Peter Bernhardt
Journal:  EJNMMI Phys       Date:  2016-08-05

4.  Treatment of symptomatic splenomegaly with low doses of radiotherapy: Retrospective analysis and review of the literature.

Authors:  Carolina de la Pinta; Eva Fernández Lizarbe; Ángel Montero Luis; José Antonio Domínguez Rullán; Sonsoles Sancho García
Journal:  Tech Innov Patient Support Radiat Oncol       Date:  2017-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.